Is Buying MyoKardia, Inc. (MYOK) Here a Winning Strategy?

March 14, 2018 - By Kurt Siggers

The stock of MyoKardia, Inc. (NASDAQ:MYOK) is a huge mover today! The stock increased 6.82% or $3.4 during the last trading session, reaching $53.25. About 726,743 shares traded or 71.06% up from the average. MyoKardia, Inc. (NASDAQ:MYOK) has risen 11.16% since March 14, 2017 and is uptrending. It has underperformed by 5.54% the S&P500.
The move comes after 7 months positive chart setup for the $1.91B company. It was reported on Mar, 14 by We have $56.98 PT which if reached, will make NASDAQ:MYOK worth $133.91 million more.

Analysts await MyoKardia, Inc. (NASDAQ:MYOK) to report earnings on May, 8. They expect $-0.32 EPS, up 13.51 % or $0.05 from last year’s $-0.37 per share. After $-0.21 actual EPS reported by MyoKardia, Inc. for the previous quarter, Wall Street now forecasts 52.38 % negative EPS growth.

MyoKardia, Inc. (NASDAQ:MYOK) Ratings Coverage

Among 5 analysts covering MyoKardia (NASDAQ:MYOK), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. MyoKardia had 5 analyst reports since November 23, 2015 according to SRatingsIntel. The firm has “Outperform” rating by BMO Capital Markets given on Wednesday, July 20. The firm earned “Outperform” rating on Monday, November 23 by Wedbush. Wells Fargo initiated MyoKardia, Inc. (NASDAQ:MYOK) on Friday, December 4 with “Outperform” rating. Credit Suisse initiated the shares of MYOK in report on Monday, November 23 with “Outperform” rating. Cowen & Co initiated the stock with “Outperform” rating in Monday, November 23 report.

More recent MyoKardia, Inc. (NASDAQ:MYOK) news were published by: which released: “MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results” on March 08, 2018. Also published the news titled: “MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER …” on March 08, 2018.‘s news article titled: “MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in …” with publication date: February 14, 2018 was also an interesting one.

MyoKardia, Inc., a clinical stage biopharmaceutical company, engages in discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. The company has market cap of $1.91 billion. The Company’s lead product candidate is MYK-461, an orally-administered small molecule that is in Phase II clinical trials designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy . It currently has negative earnings. The firm also develops MYK-491, an orally-administered small molecule that treats genetic dilated cardiomyopathy (DCM) by restoring normal contractility in the diseased DCM heart.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.